BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pang YY, Li JD, Gao L, Yang X, Dang YW, Lai ZF, Liu LM, Yang J, Wu HY, He RQ, Huang ZG, Xiong DD, Yang LH, Shi L, Mo WJ, Tang D, Lu HP, Chen G. The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues. Cancer Med 2020;9:8004-19. [PMID: 32931665 DOI: 10.1002/cam4.3434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang WJ, He WY, Li JD, He RQ, Huang ZG, Zhou XG, Li JJ, Zeng DT, Chen JT, Wu WZ, Dang YW, Chen G. Clinical significance and molecular mechanism of angiotensin-converting enzyme 2 in hepatocellular carcinoma tissues. Bioengineered 2021;12:4054-69. [PMID: 34369278 DOI: 10.1080/21655979.2021.1952791] [Reference Citation Analysis]
2 Liang Z, He R, Luo J, Huang Z, Li J, Zhong L, Chen J, Huang S, Shi L, Wei K, Zeng J, Zeng J, Chen G. Downregulated Dual-Specificity Protein Phosphatase 1 in Ovarian Carcinoma: A Comprehensive Study With Multiple Methods. Pathol Oncol Res 2022;28:1610404. [DOI: 10.3389/pore.2022.1610404] [Reference Citation Analysis]
3 Li MJ, Yan SB, Dong H, Huang ZG, Li DM, Tang YL, Pan YF, Yang Z, Pan HB, Chen G. Clinical assessment and molecular mechanism of the upregulation of Toll-like receptor 2 (TLR2) in myocardial infarction. BMC Cardiovasc Disord 2022;22:314. [PMID: 35840880 DOI: 10.1186/s12872-022-02754-y] [Reference Citation Analysis]
4 Luo Y, Wang Y, Ma Y, Wang P, Zhong J, Chu Y. Augmented Renal Clearance: What Have We Known and What Will We Do? Front Pharmacol 2021;12:723731. [PMID: 34795579 DOI: 10.3389/fphar.2021.723731] [Reference Citation Analysis]
5 Pang YY, Li JD, Gao L, Yang X, Dang YW, Lai ZF, Liu LM, Yang J, Wu HY, He RQ, Huang ZG, Xiong DD, Yang LH, Shi L, Mo WJ, Tang D, Lu HP, Chen G. The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues. Cancer Med 2020;9:8004-19. [PMID: 32931665 DOI: 10.1002/cam4.3434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Huang HQ, Chen G, Xiong DD, Lai ZF, Liu LM, Fang YY, Shen JH, Gan XY, Liao LF, Dang YW. Down-regulation of microRNA-125b-2-3p is a risk factor for a poor prognosis in hepatocellular carcinoma. Bioengineered 2021;12:1627-41. [PMID: 33949293 DOI: 10.1080/21655979.2021.1921549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 He F, Chen G, He R, Huang Z, Li J, Wu W, Chen J, Tang Y, Li D, Pan S, Feng Z, Dang Y. Expression of IER3 in hepatocellular carcinoma: clinicopathology, prognosis, and potential regulatory pathways. PeerJ 2022;10:e12944. [DOI: 10.7717/peerj.12944] [Reference Citation Analysis]
8 Lelou E, Corlu A, Nesseler N, Rauch C, Mallédant Y, Seguin P, Aninat C. The Role of Catecholamines in Pathophysiological Liver Processes. Cells 2022;11:1021. [DOI: 10.3390/cells11061021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chen L, Lin YH, Liu GQ, Huang JE, Wei W, Yang ZH, Hu YM, Xie JH, Yu HZ. Clinical Significance and Potential Role of LSM4 Overexpression in Hepatocellular Carcinoma: An Integrated Analysis Based on Multiple Databases. Front Genet 2021;12:804916. [PMID: 35096017 DOI: 10.3389/fgene.2021.804916] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]